Trial Profile
A Double-Blind, Randomized, Placebo-Controlled, Repeat Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK706769 in Healthy Male and Female Subjects.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 29 Aug 2023
Price :
$35
*
At a glance
- Drugs GSK 706769 (Primary)
- Indications HIV-1 infections
- Focus Adverse reactions; Pharmacokinetics
- Sponsors GSK
- 30 Dec 2008 Actual end date (Sep 2008) added as reported by ClinicalTrials.gov.
- 18 Dec 2008 Status changed from recruiting to completed.
- 14 Aug 2008 New trial record.